CHIESI FARMACEUTICI S.P.A.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
A Study in Patients With Chronic Obstructive Pulmonary Disease (FAIR)
Phase 3
Terminated
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Foster® 100/6 µg/unit dose
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 113
- Registration Number
- NCT01351792
- Locations
- 🇳🇱
Department of Pulmonary Diseases - University Medical Center Groningen, Groningen, Netherlands
Pharmacokinetic Clinical Study of CHF1535 NEXT DPI® Versus CHF1535 pMDI
Phase 2
Completed
- Conditions
- Asthma
- First Posted Date
- 2011-05-06
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 24
- Registration Number
- NCT01349257
- Locations
- 🇬🇧
Medicines Evaluation Unit Ltd, Manchester, United Kingdom
Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis
Phase 3
Completed
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Drug: disodium clodronate 200 mg/4 ml with 1% lidocaineDrug: Disodium clodronate 100 mg/3,3 ml with 1% lidocaine
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 260
- Registration Number
- NCT01348243
- Locations
- 🇮🇹
Policlinico GB Rossi, Verona, Italy
Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: CHF 1535 100/6 pMDI 2 monthsDrug: CHF 1535 100/6 NEXT DPI® 2 monthsDrug: BDP DPI 2 months
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 932
- Registration Number
- NCT01345916
- Locations
- 🇵🇱
GSPZOZ Uniwersytecki Szpital Kliniczny, Łódź, Poland
Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Atimos®Drug: Serevent™Drug: Placebo
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 16
- Registration Number
- NCT01344655
- Locations
- 🇬🇧
Airway Disease Section, NHLI, Imperial College London, London, United Kingdom
Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)
Phase 2
Completed
- Conditions
- Mild Persistent Asthma
- Interventions
- Drug: PlaceboDrug: BDP/formoterol
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 18
- Registration Number
- NCT01343745
- Locations
- 🇬🇧
Respiratory Clinical Trials - Heart Lung Centre - Queen Anne Street Medical Centre, London, United Kingdom
Foster With or Without Charcoal Block or Aerochamber Plus
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: pMDI standard actuatorDevice: Aerochamber Plus spacerProcedure: charcoal block
- First Posted Date
- 2011-01-20
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 13
- Registration Number
- NCT01280175
- Locations
- 🇨🇭
CROSS Research SA, Arzo, Via F.A. Giorgioli, 14, Switzerland
A Study in Patients With Chronic Obstructive Pulmonary Disease
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Foster® 100/6 µg/unit doseDrug: Seretide Accuhaler® 500/50 µg/actuation
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 373
- Registration Number
- NCT01245569
- Locations
- 🇮🇹
Policlinico Umberto I - VIII Padiglione, Rome, Italy
A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients.
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: CHF1535 NEXT DPIDrug: BDP DPI and formoterol DPI
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 57
- Registration Number
- NCT01191424
- Locations
- 🇩🇰
Copenhagen University Hospital, Copenhagen, Denmark
🇬🇧Medicines Evaluation Unit, Manchester, United Kingdom
Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic ObstructiveAsthma
- Interventions
- Drug: BDP/formoterol NEXT DPI
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 28
- Registration Number
- NCT01176747
- Locations
- 🇩🇪
Inamed Research GmbH & Co. KG, Gauting, Germany
© Copyright 2025. All Rights Reserved by MedPath